
## A Unique Approach to HIV/AIDS Prevention

GeoVax Labs, Inc. (OTCBB: GOVX) is a clinical stage biotechnology company focused on developing and commercializing human vaccines for HIV/AIDS and other infectious agents. GeoVax's unique AIDS vaccine technology is designed for use in uninfected people to protect them from AIDS should they be exposed to the HIV-1 virus. GeoVax's preventative vaccine is currently in Phase 2a trials through the US Government sponsored HIV Vaccine Trials Network (HVTN). The vaccine may also prove effective as a treatment to reduce the need for drugs in people already infected with HIV, and the Company expects to begin a therapeutic Phase 1 trial in early 2010.

## GeoVax HIV/AIDS Vaccine

- ***Primary Target:*** Vaccinate uninfected humans in order to prevent development of AIDS (currently in Phase 2a human clinical trials).
- ***Primary Target:*** Vaccinate HIV-infected humans to reduce need for drugs (planning for commencement of Phase 1 human clinical trials).
- ***Properties:*** DNA and MVA vaccines express the three major HIV proteins to stimulate anti-HIV-1 virus antibodies and T cells (white blood cells) in vaccinated humans.
- ***Applications:*** Preventative and therapeutic treatment for HIV/AIDS.

## 19 Issued or Pending Patents

- 10 Filed Patents on various components and compositions of AIDS vaccine.
- 5 Patents controlling AIDS vaccine manufacturing processes.
- 4 Patents licensed from the NIH related to MVA vector vaccine as a vehicle to deliver HIV virus antigens and induce immune response in humans.

## Scientific Leadership

Dr. Harriet Robinson, Chief Scientific Officer, is a pioneer in DNA vaccines and a leading researcher in HIV/AIDS vaccines. A co-founder of GeoVax, she previously served as Chief of Microbiology and Immunology for the Yerkes National Primate Research Center of Emory University. The Company recently strengthened its leadership with the addition of Mark J. Newman, Ph.D., Vice President, Research and Development.

## Investment Highlights

- ***Collaboration with Leading Institutions:*** GeoVax's technology is exclusively licensed from Emory University and is the result of collaborative research conducted at Emory, the National Institutes of Health (NIH), and the Centers for Disease Control (CDC).
- ***Governmental Support – Resources:*** GeoVax's Phase 2a human clinical trials are conducted by the HVTN, funded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH.
- ***Governmental Support – Funding:*** GeoVax is the recipient of a 5 year, $18 million grant awarded in October 2007 by the NIH in support of the Company's HIV/AIDS vaccine development efforts.

## Management Team

**Robert T. McNally, Ph.D.**
*President and CEO*

**Mark W. Reynolds, CPA**
*CFO*

**Harriet L. Robinson, Ph.D.**
*Chief Scientific Officer and Co-Founder*

**Mark J. Newman, Ph.D.**
*Vice President, R & D*

## Key Information

***Stock Symbol:*** GOVX (OTCBB)

***52 Week Range:*** $0.09 - $0.38

***Market Cap (12/31/09):*** $140 mil

***Website:*** www.geovax.com

***Investor Relations Contact:***
Leslie Loyet
Financial Relations Board
(312) 640-6672
lloyet@mww.com

***Media Relations Contact:***
Nikki Snodgrass
Financial Relations Board
(312) 640-6732
nsnodgrass@mww.com

## HIV / AIDS Facts

***Statistics directly impacting future market for GeoVax AIDS vaccine***

- ***2.1 Million*** Children with HIV/AIDS in 2008
- ***31.3 Million*** Adults Living with HIV/AIDS in 2008
- ***2.0 Million*** Deaths in 2008
- ***25 Million*** Deaths through 2008
- ***2.7 Million*** New Infections in 2008
- ***60 Million*** Total Infections through 2008

## Vaccine Technology

GeoVax's unique two component vaccine combines DNA priming with live vector boosting (MVA) to elicit high levels of cytolytic T cells (a type of white blood cell) and blocking antibodies. Both the DNA prime and MVA boost express the three major proteins of the HIV-1 virus and produce non-infectious HIV-like particles. This multi-protein approach optimizes protection and limits escape by eliciting a broad multi-target cytolytic T cell response and protective binding antibody to the natural form of the HIV envelope. The vaccine has demonstrated excellent safety in over 200 inoculated humans.

The vaccine is the result of a multiyear collaboration between researchers at the Emory Vaccine Center, the NIH, and the CDC. This collaboration has developed an AIDS vaccine for subtype B, which is most common in North America, the European Community, Japan, and Australia. Vaccines for HIV-1 subtypes in other regions of the world are under development and will build on the success of the subtype B vaccine.

## Preventative Vaccine: Currently in Phase 2a Trials

After promising data were obtained in pre clinical prevention trials conducted at Emory's Yerkes Primate Center between 1998 and 2002, GeoVax's vaccine technology began human testing in Phase 1 clinical trials funded and managed by the NIH sponsored HVTN. On the basis of the safety and immune response data in these trials, the vaccine is currently in Phase 2a trials through the HVTN. During the past 20 years the HVTN has sponsored over 80 Phase 1 trials for the initial evaluation of safety and immunogenicity of HIV/AIDS vaccines. GeoVax's vaccine is only the fifth of these vaccines to merit moving to an HVTN Phase 2 trial.




## Therapeutic Vaccine: Phase 1 Trials Planned

Highly promising data obtained at the Yerkes National Primate Center have demonstrated the ability of prototypes of the GeoVax vaccine to control infections in already infected non-human primates. In these vaccine trials, primates were infected, placed on oral medication, vaccinated and then taken off drugs to determine the ability of the vaccine to control the infection in the absence of continuing drug treatment. On the basis of these encouraging results, human trials testing the ability of the GeoVax vaccine to act as a therapy are being planned and, subject to FDA approval, are expected to commence in early 2010. These trials will be conducted in individuals who were placed on anti retroviral therapy within their first year of infection. If the vaccine successfully replaces the need for drugs in these individuals, trials will be extended to individuals placed on drugs and vaccinated within the first few years of infection.




**GeoVax Labs, Inc.** · 1900 Lake Park Drive, Suite 380, Smyrna, Georgia 30080 USA
*phone:* (678) 384-7220 · *fax:* (678) 384-7281 · e*fax:* (678) 384-7283 · investor@geovax.com · www.geovax.com

GeoVax℠ Vaccines Serving Humanity

# Management Profiles

## Donald (Don) G. Hildebrand

### *Chairman and Co-Founder*

Don Hildebrand's 30-year bio-career consists of successfully launching, building and managing biotechnology and biopharmaceutical companies globally. He has led teams developing, licensing and commercializing numerous vaccines and pharmaceutical products, including the first poxvirus-vectored recombinant vaccines, first genetically-engineered bacterial subunit vaccines, first recombinant vaccinia-rabies vaccine for oral administration in the U.S. and numerous other vaccines and pharmaceutical products for animal health. In 2002, Mr. Hildebrand co-founded GeoVax Labs, Inc. and served as its President and CEO until April 2008.

As former North American President and CEO of Rhone Merieux, Inc., Don Hildebrand grew the company from a staff of five with no sales to more than 1,100 people with sales exceeding several hundred million dollars. Hildebrand was promoted to Global Vice President of Merial, Ltd. after a global merger, overseeing worldwide biological research, development, technical service and operational activities. Merial Limited is the world's largest animal health company with annual sales exceeding $2.2 billion.

Prior to Rhone Merieux, Hildebrand founded Biocraft, Ltd., which was later sold to Solvay & Cie. He became Solvay's Director of Biological Operations, Research, Development and Manufacturing, initiating startup biological manufacturing and R&D companies in Brazil, Japan, Mexico, Argentina and Canada.

Don Hildebrand has served on the Board of Directors of the following entities: GeoVax Labs, Inc.; Select Laboratories, Inc.; University of Georgia Research Foundation; Vaxin Pharmaceuticals, Inc. (human vaccine-biopharmaceutical company); First American Bancorp of Georgia; Rhone Merieux, Inc.; RM de Mexico, Inc.; RM Technologies, Inc.; Biocraft, Ltd; University of Wisconsin – SCVM Board of Visitors; and the Athens/Clarke County GA Economic Development Foundation.

Hildebrand has a Microbiology degree from the University of Wisconsin (Madison) and has taken advanced management courses at Harvard Business School, Marquette University and others.

## Robert (Bob) T. McNally, Ph.D.

### *President and Chief Executive Officer*

Bob McNally became President and CEO of GeoVax Labs, Inc., in April 2008, after serving on its Board of Directors since 2006. He was previously Co-Founder and CEO of Cell Dynamics LLC. Cell Dynamics specialized in the recovery and GMP processing of human organs and tissues used for biotech and cellular medical therapies. During the period 1984 to 1998, Dr. McNally was Co-Founder and Sr. Vice President of Clinical Research for CryoLife, Inc., the market leader in transplantable human tissues including cryopreserved heart valves, veins, ligaments and tendons of the knee as well as a manufacturer of protein-derived surgical adhesives. Dr. McNally led and helped launch the company from startup through going public on the NASDAQ and NYSE.

Dr. McNally received a Bachelor of Electrical Engineering (B.E.E.) degree from Villanova University, and has a Ph.D. in Biomedical Engineering from the University of Pennsylvania. He has authored numerous patents and publications in the field of transplantable tissues and is a frequent speaker for business development in Georgia and student groups.

Currently, Dr. McNally serves as a member of the advisory boards of the Petit Institute for Bioengineering and Dupree College of Management at the Georgia Institute of Technology. He is an elected fellow of the American Institute for Medical and Biological Engineering, is a past Chairman for the Georgia Biomedical Partnership, a trade association, and is recipient of the 2004 Biomedical Industry Growth Award for the State of Georgia.

## Harriet L. Robinson, Ph.D.

### *Chief Scientific Officer and Co-Founder*

Harriet Robinson is the developer of GeoVax' HIV-1 AIDS vaccine technology. One of the world's leaders in AIDS vaccine research, she was Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center and the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University before joining GeoVax.

Dr. Robinson has published extensively on HIV/AIDS vaccine research as well as viral-induced cancers. Her pioneering studies on the development of DNA vaccines demonstrated not only that DNA could raise protective immunity for viral infections, but also identified methods of DNA delivery that could be used to control the type of immune responses raised by DNA vaccines.

Her early work with HIV vaccines demonstrated that DNA alone would not be sufficient to raise protective immunity for HIV. She then combined DNA with protein boosters or live viral-vectored boosters to show that the most effective control was through a combination of DNA prime and viral-vectored boosters. Her most recent work has developed single multi-protein expressing HIV vaccine DNAs, and working with the NIAID-NIH, single multi-protein expressing HIV-1 MVA vaccines. These are the vaccines GeoVax has licensed for commercial development for a DNA prime and MVA boost vaccine.

Dr. Robinson has published extensively on HIV/AIDS vaccine research with more than 130 scientific journal publications, 45 monograph reviews and six book chapters authored. She has served on national and international committees for the NIH, the US Food and Drug Administration, and the World Health Organization. She has chaired the Nominating Committee of the American Society of Microbiology, and has been a member of the Board of Governors for the American Academy of Microbiology and a consultant for the Gates Foundation HIV Enterprise. She was elected to the American Academy of Microbiology and was recently elected Fellow of the American Association for the Advancement of Science (AAAS) by her peers in the scientific community.

Dr. Robinson received her B.A. from Swarthmore College and her Ph.D. in Microbiology from the Massachusetts Institute of Technology.

## Mark W. Reynolds, CPA

### *Chief Financial Officer*

Mark Reynolds joined GeoVax in October 2006 as Chief Financial Officer and Corporate Secretary. Mr. Reynolds is a seasoned financial executive with over 25 years of experience with both private and publicly-held companies. He has an in-depth knowledge of SEC compliance and reporting and is experience in public company fund raising.

Prior to joining the Company, Mr. Reynolds was a financial consultant to public and private companies in the biotechnology and consumer healthcare fields, serving as a part-time Chief Financial Officer. From 1988 to 2002, Mr. Reynolds was first Controller and later Chief Financial Officer for CytRx Corporation, a publicly-held biopharmaceutical company. Mr. Reynolds began his career as an auditor with Arthur Andersen & Co. He is a Certified Public Accountant and earned a Masters Degree in Accounting from the University of Georgia.

## Mark J. Newman, Ph.D.

### *Vice President, Research and Development*

Mark Newman joined GeoVax in January 2010 and serves as the Company's Vice President of Research and Develoment. Prior to joining GeoVax, Dr. Newman was Vice President, research and development for PaxVax, Inc. where he led research and preclinical development of Adenovirus vectored vaccine candidates. During his professional life, he has worked on the development of HIV, influenza and cancer vaccines and led active programs on adjuvant and vaccine delivery technologies. Over the past 20 years, Dr. Newman has served in various senior management roles within the biotechnology field with a focus on HIV/AIDS vaccines at Pharmexa, Inc., Epimmune, Inc., Vaxcel, Inc., Apollon, Inc., and Cambridge Biotech Corporation.

Dr. Newman holds B.Sc. and M.Sc. degrees from Ohio State University. He also holds a Ph.D. in Immunology from the John Curtin School of Medical Research at the Australian National University. In his scientific career, he successfully secured peer-reviewed grants and contracts, is an inventor on seven issued patents, and an author of more than 100 peer-reviewed scientific papers. He has provided extensive service to the field of HIV/AIDS vaccines by serving on extramural panels for the review of US NIH-sponsored HIV/AIDS and vaccine research programs.